Chugai Pharmaceutical Co., Ltd. Stock OTC Markets
Stocks
CHGCY
US1712691039
Pharmaceuticals
OTC Markets Traded|
Market Closed -
OTC Markets
15:58:36 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 21.50 USD | +0.47% |
|
+3.61% | -18.16% |
| 08-21 | Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets | MT |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 11,099B 70.71B 61.66B 58.22B 52.87B 99.05B 6,785B 99.47B 697B 269B 3,450B 266B 260B | P/E 2026 * |
21.9x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 10,189B 64.91B 56.6B 53.45B 48.53B 90.93B 6,229B 91.31B 640B 247B 3,167B 244B 238B | EV / Sales 2026 * |
7.34x | EV / Sales 2027 * | 6.51x |
| Free-Float |
38.12% | Yield 2026 * |
2.02% | Yield 2027 * | 2.3% |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| CHGCY | Delayed | |
Boerse Muenchen
| CUP0 | Real-time | |
|
Deutsche Boerse AG
| CUP0 | Delayed |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | +0.47% | ||
| 1 week | +3.61% | ||
| Current month | -0.23% | ||
| 1 month | +0.14% | ||
| 3 months | -8.28% | ||
| 6 months | -22.10% | ||
| Current year | -18.16% |
| 1 week | 20 |  | 21.96 |
| 1 month | 20 | | 22.96 |
| Current year | 20 | | 34.84 |
| 1 year | 20 | | 34.84 |
| 3 years | 13.85 | | 34.84 |
| 5 years | 10.99 | | 34.84 |
| 10 years | 4.49 | | 100 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 63 | 2021-02-28 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | 59 | 2024-03-27 |
Kazuhiko Nishi
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
BRD | Director/Board Member | 63 | 2020-02-29 |
Iwaaki Taniguchi
BRD | Director/Board Member | 59 | 2024-03-27 |
| Director/Board Member | 51 | 2025-02-28 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.47% | +3.61% | - | - | 70.58B | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,027B | |
| -0.09% | +1.66% | +55.02% | +66.18% | 651B | |
| -0.02% | +2.66% | +18.91% | +71.47% | 467B | |
| -1.22% | +3.66% | +36.44% | +38.32% | 350B | |
| -0.79% | +2.73% | +19.03% | +25.08% | 268B | |
| +0.58% | +6.76% | +11.13% | +16.52% | 257B | |
| +1.55% | +2.20% | +39.81% | +46.55% | 205B | |
| +0.79% | +1.84% | -28.27% | -56.71% | 190B | |
| -0.52% | +4.45% | +32.12% | +98.51% | 187B | |
| Average | +0.23% | +2.96% | +26.15% | +45.30% | 400.23B | |
| Weighted average by Cap. | +0.23% | +3.01% | +35.17% | +61.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1,388B 8.84B 7.71B 7.28B 6.61B 12.39B 849B 12.44B 87.23B 33.66B 431B 33.22B 32.48B | 1,529B 9.74B 8.49B 8.02B 7.28B 13.64B 935B 13.7B 96.06B 37.07B 475B 36.59B 35.77B |
| Net income | 506B 3.23B 2.81B 2.66B 2.41B 4.52B 309B 4.54B 31.81B 12.28B 157B 12.12B 11.85B | 583B 3.72B 3.24B 3.06B 2.78B 5.21B 357B 5.23B 36.66B 14.15B 181B 13.96B 13.65B |
| Net Debt | -910B -5.8B -5.06B -4.77B -4.34B -8.12B -556B -8.16B -57.18B -22.07B -283B -21.78B -21.3B | -1,151B -7.33B -6.39B -6.04B -5.48B -10.27B -703B -10.31B -72.31B -27.9B -358B -27.54B -26.93B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | US$21.50 | +0.47% | 219,494 |
| 26-09-17 | US$21.40 | +4.19% | 278,264 |
| 26-09-16 | US$20.54 | -1.15% | 221,870 |
| 26-09-15 | US$20.78 | +0.14% | 907,760 |
| 26-09-14 | US$20.75 | 0.00% | 301,525 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4519 Stock
- CHGCY Stock
Select your edition
All financial news and data tailored to specific country editions
